Diagnosis and Treatment of Hepatoblastoma: An Update by Zhu, Chengzhan et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Diagnosis and Treatment of 
Hepatoblastoma: An Update
Chengzhan Zhu, Bingzi Dong, Xin Chen and Qian Dong
Abstract
Hepatoblastoma is a rare but the most common solid tumor in children. The 
incidence is gradually increasing. The international collaboration among four 
centers in the world has greatly improved the prognosis of hepatoblastoma. They 
formed the Children’s Hepatic Tumor International Collaboration (CHIC) to stan-
dardize the staging system (2017 PRETEXT system) and the risk factors for tumor 
stratification. Multimodal therapy has become the standard for the management of 
hepatoblastoma, including surgical resection, liver transplantation, chemotherapy, 
and so on. Surgery is the primary treatment of early stage hepatoblastoma. Three-
dimensional reconstruction is helpful for preoperative evaluation of large tumors, 
assisting extended hepatectomy for patients in PRETEXT III or IV. Neoadjuvant 
therapy is useful for reducing the tumor volume and increasing the resectability. 
Primary liver transplantation is recommended for advanced hepatoblastoma. The 
lungs are the most common metastatic organ, the treatment of which is critical for 
the patient’s long-term survival. We reviewed the recent progress in the diagnosis 
and treatment of hepatoblastoma.
Keywords: hepatoblastoma, PRETEXT, stratification, neoadjuvant, surgical 
resection, liver transplantation
1. Introduction
Hepatoblastoma is the third most commonly diagnosed intra-abdominal solid 
tumor [1]. It is also the most common primary hepatic malignancy in children [2]. 
More than 90% of hepatoblastoma occur in children under the age of 5 years [3, 4]. 
Although its absolute incidence is very low, its growth rate is gradually increasing, 
which increased from 1.89 per 1,000,000 in 2000 to 2.16 per 1,000,000 in 2015, 
with an annual percentage change of 2.2%. This increase mainly occurs in male chil-
dren between 2 and 4 years of age, which was found to be an independent predictor 
for short overall survival [5]. With the development of multimodal treatment and 
cooperation between international organizations, the prognoses have been greatly 
improved in recent years [6].
2. Diagnosis
Clinical manifestations are not typical at the early stage of hepatoblastoma. 
There would be epigastric or total abdominal distention, nausea, vomit, loss of 
appetite, abdominal pain, diarrhea, jaundice, even varicosity of abdominal wall, 
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and dyspnea. Another clinical feature is often accompanied by fever, and the 
temperature can reach 39–40°C. About 3% of patients have sex hormone and sexual 
organ development abnormalities. And a few children have obvious osteoporosis 
and pathological fracture.
Physical examination could find diffuse or nodular enlargement of the liver, 
of which the volume varies, sometimes with splenomegaly and varicosity of the 
abdominal wall. Abdominal pain and abdominal muscle tension may be due 
to tumor rupture. In the late stage, the hepatoblastoma progresses rapidly and 
cachexia appeared soon.
Alpha fetoprotein (AFP) increases in more than 90% of patients, which is a 
specific indicator for hepatoblastoma and important for disease follow-up. Age 
should be considered when analyzing the clinical significance of AFP. The average 
AFP of the newborn is about 62.7ng/ml, and it reaches the peak in the first month 
after birth, the average AFP is about 1200 ng/ml. After three months, it decreases 
to 3.15ng/ml (the level of normal adult). In addition, the LDH, cholesterol, and 
alkaline phosphatase are also increased. The liver function is normal at early stage, 
middle, and late stage.
Imaging is necessary for diagnosis and preoperative evaluation, including tumor 
location, number, and the relationship with peripheral blood vessels and organs. 
The commonly used examination includes ultrasound, CT, MRI, angiography, etc.
Enhanced CT and MRI are important imaging studies, which are recommended. 
However, due to the difficulty of MRI examination for children, we usually choose 
enhance CT and reconstruct the images into three-dimensional images to under-
stand the spatial structure of the tumor and the anatomical relationship with the 
blood vessels.
Additionally, the deep exploration of CT/MRI images is also important for the 
overall evaluation of hepatoblastoma. Identifying the CT/MRI image features of 
hepatoblastoma will help distinguish the more malignant tumor, which is poten-
tially useful for guiding the clinical treatment. A study of 34 patients, aimed at 
studying contrast-enhanced CT characteristics of hepatoblastoma associated with 
metastatic disease and patient outcomes, found that irregular tumor margins, 
vascular invasion, capsule retraction, and PRETEXT staging are associated with 
poor patient prognosis. Among them, irregular tumor margins are the only imaging 
features that are significantly associated with more aggressive tumor subtypes [7]. 
For investigating the image characteristics, artificial intelligence has demonstrated 
remarkable progress in image recognition tasks. Radiomics is used to investigate 
the quantitative features that are invisible to the naked eye from conventional 
image with methods of artificial intelligence. The image features could be used to 
predict the pathology characteristics, therapeutic response, and survival. Previous 
studies have evaluated the value of radiomics in adult liver cancer. The results were 
achieved, particularly in the preoperative prediction of pathological features and 
postoperative recurrence [8, 9].
3. International collaboration
3.1 The children’s hepatic tumor international collaboration (CHIC)
The four centers in the world that have performed prospective controlled studies 
of hepatoblastoma joined forces to form the CHIC. It includes the International 
Childhood Liver Tumor Strategy Group (SIOPEL), the Children’s Oncology Group 
(COG), the German Society for Pediatric Oncology and Hematology (GPOH), and 
the Japanese Study Group for Pediatric Liver Tumors (JPLT). Such international 
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cooperation provides a large-scale database for clinical trials. The CHIC has devel-
oped a centralized online platform that combines data from eight completed clinical 
trials to form a database of 1605 hepatoblastoma cases treated between 1988 and 
2008. The resulting data set has been used for investigating the relationship between 
the patient prognosis and the tumor characteristics and patient stratification for 
treatment selection and follow-up. And the collaboration has led to a uniform imple-
mentation of staging system (PRE-Treatment EXTent of tumor, PRETEXT), which 
is helpful for systemically evaluating the hepatoblastoma at diagnosis and useful 
for establishing consensus classification. Moreover, pathologists in the collabora-
tion have established a new histopathological consensus classification for pediatric 
liver tumors. There have also been advances in chemotherapy treatments and liver 
transplantation for unresectable tumors. These advances will be further evaluated in 
the upcoming Pediatric Hepatic International Tumor Trial (PHITT) [10].
3.2 2017 PRETEXT and risk stratification
Imaging is an important basis for disease assessment and treatment selection. The 
PRETEXT system has been firstly proposed for staging and risk stratification for hep-
atoblastoma in 1992 [11]. The PRETEXT system is used to classify the tumor extent 
before treatment, which has a good prognostic value in patients with hepatoblastoma. 
The PRETEXT system has been widely used to evaluate the hepatoblastoma in recent 
years, which could stratify patients into groups with different prognosis.
The 2017 PRETEXT has updated the 2005 PRETEXT definitions [12]. The liver 
was divided into four sections. For PRETEXT I, II, and IV groups, there were no 
obvious differences between 2017 PRETEXT and 2005 PRETEXT. For PRETEXT I 
group, the tumor involves only one of the two lateral sections (right posterior and 
left lateral section). For PRETEXT II group, the tumor involves the left lobe, right 
lobe, left medial section only, and right anterior section only; two separate tumors 
involves the two lateral sections or the caudate lobe only. For PRETEXT III group, 
the tumor involves three sections of the liver, leaving only one normal section. For 
PRETEXT IV group, the tumor involves all four sections. The 2017 PRETEXT has 
mainly standardized the PRETEXT annotation factors, preparing the future clinical 
trials. It includes hepatic venous/inferior vena cava involvement (V), portal venous 
involvement (P), extrahepatic disease contiguous with the main liver tumor (E), 
multifocality (F), and tumor rupture (R) [12].
Many single centers have put effort to investigate the prognostic factor of 
hepatoblastoma [13–16]. But the results were limited due to the small patients’ 
number and the use of multiple disparate staging systems. CHIC has created a new 
staging system to staging and risk stratification in children with hepatoblastoma, 
named the Children’s Hepatic tumors International Collaboration-Hepatoblastoma 
Stratification (CHIC-HS). Based on a 5-year event-free survival and clinical appli-
cability, the system was established with risk factors including PRETEXT groups, 
metastatic disease, age, AFP concentration, PRETEXT annotation factors (VPEFR), 
and surgically resectable at diagnosis [17]. PRETEXT group is the primary and most 
important for risk stratification. If the tumor is resectable at diagnosis for patients 
of PRETEXT I/II group, they are in very low or low risk. After PRETEXT group, 
metastatic disease is the first risk factor for stratification. All patients with meta-
static disease were defined as high risk. Then, age ≥ 8 years in PRETEXT I, II, and 
III group and age ≥ 3 years in PRETEXT IV group were high-risk factor. For younger 
patients, AFP ≤100 ng/mL was defined as high-risk group. And VPEFR+ patients 
were in intermediate-risk group. In PRETEXT I/II group, older patients showed a 
relatively poor prognosis. But many of these tumors can be surgically resected; they 
defined the patients at 3–7 year age in the lower-risk group; patients who had low 
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PRETEXT and positive VPEFR were placed in the intermediate-risk group; patients 
with PRETEXT I and low AFP (≤100 ng/mL) should not be stratified into high-
risk group due to surgically resectable small tumors; patients with PRETEXT III 
group (younger than 8 years, no metastasis (M−) and AFP 100–1000 ng/mL) were 
defined as intermediate risk due to the poor 5-year event-free survival. CHIC-HS is 
by far the most complete system for risk stratification of pediatric hepatoblastoma 
and has important guiding significance for guiding individualized treatment [17]. 
Further study should also pay attention to the prognostic effect of treatment selec-
tion, such as anatomical or nonanatomical partial hepatectomy [18] and the dosage 
of chemotherapy [19, 20].
4. Treatment
Multimodal therapy is recommended for the management of hepatoblastoma, 
including surgical resection, liver transplantation, chemotherapy, or radiofrequency 
ablation [21]. Multimodal therapy can improve tumor remission rate of children with 
advanced hepatoblastoma and prolong the survival. Surgical resection is the pre-
ferred treatment of resectable hepatoblastoma at the time of diagnosis. Neoadjuvant 
chemotherapy could improve the rate and safety of complete surgical resection for 
unresectable hepatoblastoma. Liver transplantation is one of the main treatments for 
unresectable hepatoblastoma [22, 23]. Prognosis has been greatly improved due to 
advances in chemotherapeutic agents and dosing regimens as well as innovations in 
surgical procedures, including the preoperative three-dimensional reconstruction, 
the usage of energy device, and liver transplantation. The management of high-risk 
patients and patients with recurrent or metastatic disease remains challenging [21].
4.1 Surgical resection for hepatoblastoma
Hepatectomy is the first choice for hepatoblastoma. It is suitable for PRETEXT I, 
II, and part of III patients. For most PRETEXT III and IV patients, chemotherapy is 
preferred first. Then, reevaluate the tumor and decide the treatment, hepatectomy 
or liver transplantation. However, there is still controversy about whether surgery 
should be performed first or chemotherapy first and the selection of extended 
hepatectomy or liver transplantation.
4.1.1 Preoperative or postoperative chemotherapy
Over the past 40 years, the management of hepatoblastoma has changed 
significantly. For patients with unresectable tumors, neoadjuvant chemotherapy 
has become the standard treatment which can lead to a significant reduction in 
preoperative tumors and sometimes even complete ablation [24]. Neoadjuvant 
chemotherapy may facilitate partial hepatectomy by withdrawal of the tumor 
boundary from the confluence of portal vein bifurcation, hepatic veins, and inferior 
vena cava. And the tumor volume of hepatoblastoma could be significantly resolved 
with increasing neoadjuvant chemotherapy cycles [25]. For patients who underwent 
cisplatinum-based neoadjuvant and postoperative chemotherapy, microscopically 
positive resection margin did not affect the overall survival rate. And the “wait-
and-see policy” is recommended [26].
For patients with hepatoblastoma that could be resected at diagnosis, postopera-
tive chemotherapy with cisplatin, fluorouracil, and vincristine is useful to control 
the disease progression [27]. And for the subtype of pure fetal histology hepato-
blastoma, complete surgical resection can achieve good survival without additional 
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chemotherapy. Further study should be performed to identify the patients for 
whom chemotherapy is not necessary [28].
4.1.2 Extended hepatectomy or liver transplantation
The management of patients in PRETEXT III or IV was difficult, including the 
selection between an aggressive liver resection and liver transplantation. There 
has been several study comparing the prognosis of partial hepatectomy and liver 
transplantation, the 5-year overall survival rate was 92% in patients who were 
performed partial hepatectomy, and about 83% in patients who underwent liver 
transplantation [29–32].
Although primary liver transplantation is recommended for POSTTEXT III 
and IV hepatoblastoma, some of the patients may be possible to perform extended 
hepatectomy after careful preoperative evaluation. In a prospective study that 
involved 18 patients with PRETEXT III and IV, extended major hepatic resection is 
safe and feasible with a comparable prognosis. The prognosis was similar with liver 
transplantation, while patients could avoid long-term immunosuppressive treat-
ment. But there should always be a potential donor for salvage liver transplantation 
[33, 34]. A study including 24 patients performed liver transplantation or extensive 
liver resection. Two patients in five who underwent liver transplantation experienced 
tumor recurrence and death within a mean period of 6 months, while 6 patients 
were recurrent in the extended hepatectomy group, with 63.2% event-free survival 
and 94.7% overall survival rate. The results support extensive surgical resection in 
patients of advanced tumor [35]. Although the surgical resection is complicated and 
sometimes remains positive or close negative margins, the patients could have good 
outcomes. Combined with neoadjuvant therapy, extensive surgical resection may 
spare the morbidity of orthotopic liver transplantation. And it will offer an alterna-
tive treatment for patients who are ineligible for liver transplantation [36].
In our center, we have performed extended hepatectomy for 27 cases of 
PRETEXT or POSTEXT III and IV, the 3-year disease-free survival was 75.0%, and 
the overall survival was 87.5%.
4.1.3 Does postoperative complication affect prognosis
Neoadjuvant therapy has become the standard treatment for unresected hepato-
blastoma. After neoadjuvant therapy, tumor volume may reduce, and surgical resec-
tion could be safely performed [37]. Although the patients may have good survival, 
neoadjuvant therapy may be related with postoperative complications. A study 
assessing the surgical outcomes focusing on resection margins, postoperative com-
plications, 30-day mortality, and overall survival found that patients who underwent 
partial hepatectomy after chemotherapy experienced high rate of surgical complica-
tions (58%). But the complications were not detrimental to survival [29]. In another 
report, the incidence of complications after surgical resection following adjuvant 
chemotherapy is high and is associated with overall survival in high-risk hepatoblas-
toma. One of the possible reasons is that postoperative complication will delay the 
chemotherapy [38]. In our experience, precise preoperative evaluation of the anatomy 
of tumor and intrahepatic vascular with three-dimensional (3D) reconstruction and 
compare with the intraoperative situation will ensure the safety of surgery.
4.2 3D reconstruction facilitates surgical resection
Three-dimensional reconstruction has been widely used in preoperative evalu-
ation and assisting hepatectomy [39] or living donor liver transplantation [40]. 
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3D simulation software could reconstruct the whole liver, tumor, and intrahepatic 
vascular, clearly displaying the anatomical variation and the correlation of tumor 
with the surrounding vascular. It is helpful for making the precise surgical plan 
and enables individualized anatomic hepatectomy for each pediatric patient with 
hepatoblastoma. For surgical resection, precisely understanding the location of 
tumor and the relation of tumor with the surrounding vascular and accurately 
evaluating the remnant liver volume are important for safe hepatectomy of giant 
hepatoblastoma. In our center, we have used a novel virtual hepatectomy simula-
tion software named Hisense CAS for preoperative evaluation. The Hisense CAS 
software could simulate a 3D liver image quickly and accurately with DICOM files 
of contrast-enhanced CT. With the Hisense CAS, we could confirm the anatomical 
relationship of tumor with the surrounding vascular from any direction, preop-
eratively mimic hepatectomy by extracting Glisson territory for anatomical liver 
resection or nonanatomical hepatectomy, automatically calculate the remnant liver 
volume, and navigate the liver resection during operation [41, 42]. As shown in 
Figure 1, with the help of 3D reconstruction, we performed extended hepatectomy 
for the patients. In total, we have performed extended hepatectomy for 27 patients 
in PRETEXT or POSTTEXT III and IV. All the hepatoblastoma were successfully 
removed with no complications. There were shorter operation time and less intra-
operative bleeding in the reconstructing group. And the postoperative hospital stays 
tended to be shorter [41, 42].
4.3 Liver transplantation in unresectable hepatoblastoma
Although extended hepatectomy for advanced hepatoblastoma has achieved 
favorable results, liver transplantation is still the only treatment for unresectable 
hepatoblastoma.
Liver transplantation can achieve a good prognosis for patients with hepatoblas-
toma, with a 5-year survival rate of 86% and a 10-year survival rate of about 80% 
[32, 43]. Compared with deceased donor transplantation, the prognosis of living 
liver transplantation was a little better (5-year survival rates were 83.3 and 77.6%). 
And compared with salvage liver transplantation, primary liver transplantation 
has a better prognosis (5-year survival rates were 82 and 30%) [31]. Compared 
with liver transplantation performed before 2010, patients who received liver 
transplantation after 2010 have a better prognosis (5-year survival rates were 82.6 
and 75.1%) [43]. Preoperative liver metastasis, tumor lysis after chemotherapy, and 
perioperative anticoagulation can significantly improve the prognosis of patients 
with liver transplantation. And the outcome was not affected by tumor pathology 
[44]. For unresectable hepatoblastoma, vascular infiltration and poor resection are 
often present, and liver transplantation has become the first choice [45]. Adjuvant 
chemotherapy after transplantation can significantly improve the long-term 
prognosis of patients [22]. For unresectable hepatoblastoma, the pretransplantation 
trend of alpha-fetoprotein levels after live donor liver transplantation can be used as 
an indicator of predictive recurrence. Since the AFP response cannot be accurately 
predicted before each chemotherapy cycle, liver transplantation may be appropri-
ate if the AFP level does not decrease after the last cycle and before AFP levels are 
found to rise again [46].
4.4 Treatment after metastasis
The lung is the most common metastatic organ of hepatoblastoma. In addition to 
lung, brain and bone metastases have also been reported [12, 47]. At the first diagnosis 
of hepatoblastoma, 17% of patients had pulmonary metastases [48]. Patients with lung 
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metastasis will have a poor overall prognosis. Therefore, a CT scan of the lung should be 
performed before treatment to determine whether there is lung metastasis. Treatment 
after lung metastasis is also critical to extend the prognosis of patients. Comprehensive 
treatment of primary and metastatic lesions can improve the prognosis of patients.
The treatment of patients with synchronous lung metastasis and hepatoblas-
toma has been systemically reviewed [49]. To summarize, if the primary lesions and 
Figure 1. 
Precise evaluation of hepatoblastoma with 3D reconstruction software.
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metastases are resectable, combine resection; if unresectable, eradicate or reduce 
the metastasis by neoadjuvant chemotherapy and then flowing combined resec-
tion. For single lung metastatic nodule, surgical resection is safe and feasible for the 
treatment [50]. Neoadjuvant chemotherapy combined with surgical resection of 
primary and metastatic lesions can achieve a better prognosis for patients with lung 
metastases. Most lung metastatic lesions are sensitive to chemotherapy. About half 
(26/60) of patients can achieve complete remission by chemotherapy. Then flow-
ing surgical removal of primary lesion, the patient’s survival could be significantly 
improved (3-year survival rate 67.2%) [51]. For the patients whose lung metastasis 
cannot be completely eradicated by chemotherapy, the prognosis is relatively poor 
[52]. For patients who cannot achieve complete remission, increasing the intensity 
of chemotherapy or expanding the scope of surgical resection may prolong the 
patient’s prognosis. In addition, the patients will experience poor prognosis if it 
occurs as lung metastases while on treatment [52]. If the primary liver lesion is 
resectable, chemotherapy-resistant lung lesions should be surgically removed 
before, after, or at the same time as liver tumor surgery. In patients with unresect-
able primary liver tumor, liver transplantation combined with metastasectomy can 
be performed after chemotherapy, the 5-year survival rate of which can reach 86%. 
For patients with an unremovable hepatoblastoma and residual lung metastasis, 
overall tumor burden may be an important prognostic factor for these patients [53]. 
Local treatment (e.g., transcatheter arterial chemoembolization or radiofrequency 
ablation) may be considered to reduce tumor size [49, 54]. Sometimes it is difficult 
to diagnose whether there is viability of residual lung lesions after chemotherapy; 
it will affect the operation for the primary tumor. It is difficult to determine the 
pathology of tiny lesions in imaging and find the lesions during intraoperative 
exploration; indocyanine green fluoroscopy may be helpful. But further study is 
necessary to verify the usefulness [55].
4.5 Adult hepatoblastoma
Compared with pediatric hepatoblastoma, adult hepatoblastoma has a lower 
incidence and a higher degree of malignancy [56]. There is no significant gender 
difference in the incidence of adult hepatoblastoma, and the average age of onset is 
42 years [57]. About 25% of adult hepatoblastomas are associated with hepatitis and 
cirrhosis, while it is rare in pediatric patients. Abdominal pain is the main clinical 
manifestation, and abdominal mass is the most common sign. As with children, 
surgical resection is the first choice for adult hepatoblastoma. Most hepatoblastomas 
are unresectable at diagnosis; chemotherapy can be used for patients who cannot 
be resected to gain opportunities for surgery [58]. Chemotherapy protocols are not 
standardized, and there was no statistically significance in survival rate between 
patients treated with drugs or TACE and patients not treated [57]. Due to low 
incidence, liver transplantation has yet to be fully evaluated. The prognosis of adult 
hepatoblastoma is extremely poor. The median survival time was 8 months and a 
1-year survival rate of 39.2% after treatment [59]. And patients had a longer survival 
if operation was performed [59]. Compared with nonsurgical treatment, surgery has 
a better prognosis. Hepatic multilobed involvement, embryonic histology, multifo-
cal nodules, and AFP <100 or AFP > 1000 are the poor prognostic factors [60].
5. Conclusions
In summary, surgical resection is the primary treatment for hepatoblastoma. 
Preoperative three-dimensional reconstruction can improve the resection rate 
9Diagnosis and Treatment of Hepatoblastoma: An Update
DOI: http://dx.doi.org/10.5772/intechopen.90830
Author details
Chengzhan Zhu1,2, Bingzi Dong2, Xin Chen3 and Qian Dong2,3*
1 Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of 
Qingdao University, Qingdao, China
2 Shandong Key Laboratory of Digital Medicine and Computer Assisted Surgery, 
The Affiliated Hospital of Qingdao University, Qingdao, China
3 Pediatric Surgery Department, The Affiliated Hospital of Qingdao University, 
Qingdao, China
*Address all correspondence to: 18661801885@163.com
of the tumor and the safety of the resection. For patients who cannot be directly 
resected, the tumor volume can be reduced by neoadjuvant therapy and then 
surgically treated. Liver transplantation is the best treatment for unresectable 
hepatoblastoma and has a good prognosis. For patients with distant metastasis, che-
motherapy or metastasis resection combined with primary resection can effectively 
control disease progression.
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